Goldman Sachs Maintains Buy on Olema Pharmaceuticals, Lowers Price Target to $27

Benzinga Newsdesk www.benzinga.com Negative 49.2%

Neg 49.2% Neu 0% Pos 0%

Goldman Sachs analyst Richard Law maintains Olema Pharmaceuticals (NASDAQ:OLMA) with a Buy and lowers the price target from $38 to $27.